A pajzsmirigy autonóm adenoma ultrahangvezérelt perkután etanol-szkleroterápiája.

Translated title of the contribution: Percutaneous ultrasound-guided ethanol sclerotherapy of autonomous thyroid nodules

T. Solymosi, A. Erdei, D. Nagy, I. Gál

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Percutaneous ethanol injection therapy for autonomously functioning thyroid nodules has been performed in 53 patients. 36 patients suffered from hyperthyroidism, and 17 patients had subclinical hyperthyroidism. Ethanol was administered under ultrasonographic guidance in 2-6 sessions depending on the size of the nodule Local neck pain was the most often adverse effect. Transient dysphonia occurred in 3 patients. A subacute granulomatous thyroiditis-like reaction within 1 week after the last session occurred in 4 patients. During a 10-day steroid administration this reaction was stopped. After ethanol sclerotherapy reduction of thyroid nodular volume can be achieved. The reduction of the nodules was between 36 and 75% (mean 55 +/- 15%) of the pre-treatment volume at 6 week after therapy. In 27 of 36 hyperthyroid patients the FT4- and T3-levels became normal. Repeated sclerotherapy was successfull in 6 of the remaining 9 hyperthyroid patients. No relapse of hyperthyroidism was observed. The scintiscan showed a complete cure in 10 of 23 patients one year after PEI-therapy, while in 11 patients partial normalization of the scintiscan was observed. In 2 of 23 patients the scintiscan remained unchanged. Indication of ethanol sclerotherapy is not clear. The method appears an effective alternative procedure in patients with large nodules at high surgical risk. Under special circumstances (pregnancy or iodine-induced hyperthyroidism) ethanol sclerotherapy may be a practical alternative for toxic autonomously functioning thyroid nodules.

Original languageHungarian
Pages (from-to)2161-2165
Number of pages5
JournalOrvosi Hetilap
Volume140
Issue number39
Publication statusPublished - Sep 26 1999

Fingerprint

Thyroid Nodule
Sclerotherapy
Ethanol
Hyperthyroidism
Subacute Thyroiditis
Dysphonia
Neck Pain
Poisons
Therapeutics
Iodine
Thyroid Gland
Steroids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A pajzsmirigy autonóm adenoma ultrahangvezérelt perkután etanol-szkleroterápiája. / Solymosi, T.; Erdei, A.; Nagy, D.; Gál, I.

In: Orvosi Hetilap, Vol. 140, No. 39, 26.09.1999, p. 2161-2165.

Research output: Contribution to journalArticle

Solymosi, T, Erdei, A, Nagy, D & Gál, I 1999, 'A pajzsmirigy autonóm adenoma ultrahangvezérelt perkután etanol-szkleroterápiája.', Orvosi Hetilap, vol. 140, no. 39, pp. 2161-2165.
Solymosi, T. ; Erdei, A. ; Nagy, D. ; Gál, I. / A pajzsmirigy autonóm adenoma ultrahangvezérelt perkután etanol-szkleroterápiája. In: Orvosi Hetilap. 1999 ; Vol. 140, No. 39. pp. 2161-2165.
@article{144a19ed89684d7fa78428ef81ad879b,
title = "A pajzsmirigy auton{\'o}m adenoma ultrahangvez{\'e}relt perkut{\'a}n etanol-szkleroter{\'a}pi{\'a}ja.",
abstract = "Percutaneous ethanol injection therapy for autonomously functioning thyroid nodules has been performed in 53 patients. 36 patients suffered from hyperthyroidism, and 17 patients had subclinical hyperthyroidism. Ethanol was administered under ultrasonographic guidance in 2-6 sessions depending on the size of the nodule Local neck pain was the most often adverse effect. Transient dysphonia occurred in 3 patients. A subacute granulomatous thyroiditis-like reaction within 1 week after the last session occurred in 4 patients. During a 10-day steroid administration this reaction was stopped. After ethanol sclerotherapy reduction of thyroid nodular volume can be achieved. The reduction of the nodules was between 36 and 75{\%} (mean 55 +/- 15{\%}) of the pre-treatment volume at 6 week after therapy. In 27 of 36 hyperthyroid patients the FT4- and T3-levels became normal. Repeated sclerotherapy was successfull in 6 of the remaining 9 hyperthyroid patients. No relapse of hyperthyroidism was observed. The scintiscan showed a complete cure in 10 of 23 patients one year after PEI-therapy, while in 11 patients partial normalization of the scintiscan was observed. In 2 of 23 patients the scintiscan remained unchanged. Indication of ethanol sclerotherapy is not clear. The method appears an effective alternative procedure in patients with large nodules at high surgical risk. Under special circumstances (pregnancy or iodine-induced hyperthyroidism) ethanol sclerotherapy may be a practical alternative for toxic autonomously functioning thyroid nodules.",
author = "T. Solymosi and A. Erdei and D. Nagy and I. G{\'a}l",
year = "1999",
month = "9",
day = "26",
language = "Hungarian",
volume = "140",
pages = "2161--2165",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "39",

}

TY - JOUR

T1 - A pajzsmirigy autonóm adenoma ultrahangvezérelt perkután etanol-szkleroterápiája.

AU - Solymosi, T.

AU - Erdei, A.

AU - Nagy, D.

AU - Gál, I.

PY - 1999/9/26

Y1 - 1999/9/26

N2 - Percutaneous ethanol injection therapy for autonomously functioning thyroid nodules has been performed in 53 patients. 36 patients suffered from hyperthyroidism, and 17 patients had subclinical hyperthyroidism. Ethanol was administered under ultrasonographic guidance in 2-6 sessions depending on the size of the nodule Local neck pain was the most often adverse effect. Transient dysphonia occurred in 3 patients. A subacute granulomatous thyroiditis-like reaction within 1 week after the last session occurred in 4 patients. During a 10-day steroid administration this reaction was stopped. After ethanol sclerotherapy reduction of thyroid nodular volume can be achieved. The reduction of the nodules was between 36 and 75% (mean 55 +/- 15%) of the pre-treatment volume at 6 week after therapy. In 27 of 36 hyperthyroid patients the FT4- and T3-levels became normal. Repeated sclerotherapy was successfull in 6 of the remaining 9 hyperthyroid patients. No relapse of hyperthyroidism was observed. The scintiscan showed a complete cure in 10 of 23 patients one year after PEI-therapy, while in 11 patients partial normalization of the scintiscan was observed. In 2 of 23 patients the scintiscan remained unchanged. Indication of ethanol sclerotherapy is not clear. The method appears an effective alternative procedure in patients with large nodules at high surgical risk. Under special circumstances (pregnancy or iodine-induced hyperthyroidism) ethanol sclerotherapy may be a practical alternative for toxic autonomously functioning thyroid nodules.

AB - Percutaneous ethanol injection therapy for autonomously functioning thyroid nodules has been performed in 53 patients. 36 patients suffered from hyperthyroidism, and 17 patients had subclinical hyperthyroidism. Ethanol was administered under ultrasonographic guidance in 2-6 sessions depending on the size of the nodule Local neck pain was the most often adverse effect. Transient dysphonia occurred in 3 patients. A subacute granulomatous thyroiditis-like reaction within 1 week after the last session occurred in 4 patients. During a 10-day steroid administration this reaction was stopped. After ethanol sclerotherapy reduction of thyroid nodular volume can be achieved. The reduction of the nodules was between 36 and 75% (mean 55 +/- 15%) of the pre-treatment volume at 6 week after therapy. In 27 of 36 hyperthyroid patients the FT4- and T3-levels became normal. Repeated sclerotherapy was successfull in 6 of the remaining 9 hyperthyroid patients. No relapse of hyperthyroidism was observed. The scintiscan showed a complete cure in 10 of 23 patients one year after PEI-therapy, while in 11 patients partial normalization of the scintiscan was observed. In 2 of 23 patients the scintiscan remained unchanged. Indication of ethanol sclerotherapy is not clear. The method appears an effective alternative procedure in patients with large nodules at high surgical risk. Under special circumstances (pregnancy or iodine-induced hyperthyroidism) ethanol sclerotherapy may be a practical alternative for toxic autonomously functioning thyroid nodules.

UR - http://www.scopus.com/inward/record.url?scp=0033607054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033607054&partnerID=8YFLogxK

M3 - Article

C2 - 10533379

AN - SCOPUS:0033607054

VL - 140

SP - 2161

EP - 2165

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 39

ER -